ReviewCurrent treatment options in oncology2026
Increasing Diversity in Head and Neck Cancer Clinical Trials.
Review in Current treatment options in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementParticipation in cancer clinical trials is essential for advancing medical knowledge, improving patient outcomes, and ensuring equitable access to emerging therapies. However, oncology clinical trial participants do not reflect the population affected by cancer. In particular, racial and ethnic minorities, rural residents, and individuals from lower socioeconomic backgrounds continue to be significantly underrepresented in oncology clinical trials overall, and among trials evaluating patients with head and neck cancer (HNC), relative to their frequency in the general population. This review applies the social ecological model to identify and categorize barriers to equitable clinical trial accrual across individual, interpersonal, institutional, community, and policy levels. Addressing these multilevel barriers requires the concerted efforts of researchers, clinicians, community leaders, and policymakers. Commitment to inclusive trial design and implementation is essential to ensuring that the benefits of cancer research are equitably distributed. Clinical research must reflect the populations it seeks to serve, so that all patients, not just a select few, benefit from the future of oncology innovation.
Indexed as
Identifiers
41484522What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.